Elizabeth Asztalos
MD
Qualification
- MSc, Health Research Methodology, McMaster University (2000-2002)
- Neonatal Fellowship, Regional Perinatal Unit, Women's College Hospital (1987-1989)
- Residency, Paediatrics, The Hospital for Sick Children (1984-1987)
- MD, Faculty of Medicine, University of Toronto (1980-1984)
- BScN, Faculty of Science and Mathematics, School of Nursing, University of Windsor (1973-1977)
- BA, Faculty of Social Science, University of Windsor (1973-1976)
Other Academic and Clinical Appointments
Associate Member, Institute of Medical Sciences, University of Toronto (2021 – present)
Senior Scientist, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre (2020 – present)
Professor, Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto (2019 – present)
Research Director, Neonatal Program, Department of Newborn & Developmental Paediatrics, Sunnybrook Health Sciences Centre (2001 - present)
Staff Neonatologist, Department of Newborn & Developmental Paediatrics, Sunnybrook Health Sciences Centre (1989 - present)
At a Glance
- Dr. Asztalos’ research is focused on the development and conduct of clinical trials to explore perinatal and neonatal outcomes, and how to optimize the provision of breast milk for the preterm infant.
Research Synopsis
Dr. Asztalos' primary area is in clinical epidemiology, with the body of her work in clinical trials. Her main areas of strength are the neurodevelopmental monitoring and follow-up of high-risk infants. She was the principal investigator for the five-year follow-up study of children whose mothers participated in the Multiple Courses of Antenatal Corticosteroids (MAC-5) study, which was recently completed in 2012. She also just concluded a clinical trial on the safety and effectiveness of domperidone in breast milk production, the EMPOWER study. She is also the principal investigator for LIFT_Canada, a Canadian multi-centre RCT which will evaluate whether bovine lactoferrin will improve survival of very low birth weight infants without significant morbidities.
Recent Publications
- Feig DS, Sanchez JJ, Murphy KE, Asztalos E, Zinman B, Simmons D, Haqq AM, Fantus IG, Lipscombe L, Armson A, Barrett J, Donovan L, Karanicolas P, Tobin S, Mangoff K, Klein G, Jiang Y, Tomlinson G, Hamilton J; MiTy Kids Collaborative Group. Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial. Lancet Diabetes Endocrinol. 2023 Mar;11(3):191-202. doi: 10.1016/S2213-8587(23)00004-9. Epub 2023 Feb 3. PMID: 36746160.
- Ninan K, Liyanage SK, Murphy KE, Asztalos EV, McDonald SD. Long-Term Outcomes of Multiple versus a Single Course of Antenatal Steroids: A Systematic Review. Am J Perinatol. 2023 Feb 1. doi: 10.1055/s-0042-1760386. Epub ahead of print. PMID: 36724821.
- Sotiropoulos JX, Schmölzer GM, Oei JL, Libesman S, Hunter KE, Williams JG, Webster AC, Tarnow-Mordi WO, Vento M, Asztalos E, Shah PS, Katheria A, Seidler AL. PROspective Meta-analysis Of Trials of Initial Oxygen in preterm Newborns (PROMOTION): Protocol for a systematic review and prospective meta-analysis with individual participant data on initial oxygen concentration for resuscitation of preterm infants. Acta Paediatr. 2023 Mar;112(3):372-382. doi: 10.1111/apa.16622. Epub 2022 Dec 26. PMID: 36484640.
- Melamed N, Asztalos E. Antenatal betamethasone regimen for women at risk of preterm birth. Lancet. 2022 Aug 20;400(10352):541-543. doi: 10.1016/S0140-6736(22)01527-6. PMID: 35988553.
- Asztalos EV, Kiss A. Early Breast Milk Volumes and Response to Galactogogue Treatment. Children (Basel). 2022 Jul 13;9(7):1042. doi: 10.3390/children9071042. PMID: 35884026; PMCID: PMC9315761.
- Asztalos E. Optimizing Care for the Preterm Infant. Children (Basel). 2022 May 25;9(6):778. doi: 10.3390/children9060778. PMID: 35740715; PMCID: PMC9221890.
- Feig DS, Zinman B, Asztalos E, Donovan LE, Shah PS, Sanchez JJ, Tomlinson G, Murphy KE. Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin? Diabetes Care. 2022 Jul 7;45(7):1532-1539. doi: 10.2337/dc22-0013. PMID: 35671033.
- Ninan K, Liyanage SK, Murphy KE, Asztalos EV, McDonald SD. Evaluation of Long-term Outcomes Associated With Preterm Exposure to Antenatal Corticosteroids: A Systematic Review and Meta-analysis. JAMA Pediatr. 2022 Apr 11:e220483. doi: 10.1001/jamapediatrics.2022.0483. Epub ahead of print. PMID: 35404395; PMCID: PMC9002717.
- Ronzoni S, Cobo T, D'Souza R, Asztalos E, O'Rinn SE, Cao X, Herranz A, Melamed N, Ferrero S, Barrett J, Aldecoa V, Palacio M. Individualized treatment of preterm premature rupture of membranes to prolong the latency period, reduce the rate of preterm birth, and improve neonatal outcomes. Am J Obstet Gynecol. 2022 Mar 5:S0002-9378(22)00166-1. doi: 10.1016/j.ajog.2022.02.037. Epub ahead of print. PMID: 35257664.
- Smith J, Murphy KE, McDonald SD, Asztalos E, Aviram A, Ronzoni S, Mei-Dan E, Zaltz A, Barrett J, Melamed N. Timing of antenatal corticosteroids in relation to clinical indication. Arch Gynecol Obstet. 2022 Jan 18. doi: 10.1007/s00404-021-06362-7. Epub ahead of print. PMID: 35039883.
Current Lab Members (within the Department of Nutritional Sciences)
Marina Castro - MSc student